FTA will hurt pharmaceutical sector

It's obvious that prices of the drugs will soar, which will damage domestic clients' access to drugs, if a U.S.-Korea free trade agreement goes through and the patent period of new drugs made by the United States is extended, said an official of the Korea Pharmaceuticals Manufacturers Association.

With U.S. pharmaceutical firms looking to sell its high-priced drugs in the local market, there...